Loading patent…
AssigneeNovartis AG
InventorsJohn Louis Diener, Jiaping Gao, Rick Jerome Schiebinger
Estimating the term…
The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
A method of treating HIV-HAART induced partial lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of an FGF21 protein variant Fc fusion protein comprising amino acid sequence SEQ ID NO:
A method of treating HIV-HAART induced partial lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of an FGF21 protein variant Fc fusion protein, wherein the FGF21 protein variant Fc fusion protein is administered in the form of a pharmaceutical composition comprising a therapeutically effective amount of the FGF21 protein variant Fc fusion protein in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration, and wherein the FGF21 protein variant Fc fusion protein comprises amino acid sequence SEQ ID NO:
Dependencies are inferred from the claim text.